Related Experiment Video
Updated: Sep 19, 2025
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
Acetaldehyde dehydrogenase 1A1 upregulation drives dacomitinib-induced skin toxicity through mitochondrial
Wanying Zhou1, Xinyue Ma1, Lili Tan1
1Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, China; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
Abstract:
Dacomitinib is a pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor (TKI), approved for the first-line treatment of non-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 1(EGFR)-sensitive mutations. The use of dacomitinib is limited because of its cutaneous toxicity. Since the exact mechanism of dacomitinib-induced cutaneous toxicity is unknown, effective targeted prophylaxis and therapy remain unavailable. Our study established an animal model of dacomitinib-induced cutaneous toxicity and found that dacomitinib induced mitochondrial dysfunction and apoptosis in keratinocytes with enhanced secretion of inflammatory factors. Mechanistically, we found that the retinoid pathway in keratinocytes was activated by dacomitinib, with significant upregulation of the key enzyme acetaldehyde dehydrogenase 1A1 (ALDH1A1), which appears to be a key factor in cutaneous toxicity. ALDH1A1 knockdown reversed the apoptosis and mitochondrial dysfunction caused by dacomitinib in keratinocytes, suggesting its potential as a therapeutic target. Furthermore, silibinin was shown to mitigate dacomitinib-induced cutaneous toxicity by reducing ALDH1A1. Overall, this study highlights the critical role of ALDH1A1 in drug-induced cutaneous toxicity and its potential as an interventional target.
Insights
Dacomitinib causes skin toxicity by damaging keratinocytes via the ALDH1A1 enzyme. Targeting ALDH1A1 may prevent or treat this side effect in non-small cell lung cancer patients.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Dacomitinib, a pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor (TKI), treats EGFR-mutated non-small cell lung cancer (NSCLC).
- Cutaneous toxicity limits dacomitinib use, with unknown mechanisms hindering targeted interventions.
Purpose of the Study:
- To investigate the mechanism of dacomitinib-induced skin toxicity.
- To identify potential therapeutic targets for mitigating dacomitinib's cutaneous side effects.
Main Methods:
- Established an animal model for dacomitinib-induced cutaneous toxicity.
- Analyzed dacomitinib's effects on keratinocyte mitochondrial function, apoptosis, and inflammatory factor secretion.
- Investigated the role of the retinoid pathway and acetaldehyde dehydrogenase 1A1 (ALDH1A1) in toxicity.
- Assessed the therapeutic potential of ALDH1A1 knockdown and silibinin treatment.
Main Results:
- Dacomitinib induced mitochondrial dysfunction, apoptosis, and inflammation in keratinocytes.
- Dacomitinib activated the retinoid pathway, upregulating ALDH1A1, a key factor in skin toxicity.
- ALDH1A1 knockdown ameliorated dacomitinib-induced keratinocyte damage.
- Silibinin reduced dacomitinib-induced cutaneous toxicity by downregulating ALDH1A1.
Conclusions:
- ALDH1A1 plays a critical role in dacomitinib-induced cutaneous toxicity.
- ALDH1A1 represents a potential therapeutic target for managing dacomitinib's skin side effects in NSCLC patients.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
07:14A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation
Published on: July 13, 2018
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
The Intrinsic Apoptotic Pathway